Cannabis
Lotus Ventures Inc. Presenting at the Benzinga Cannabis Capital Conference
Detroit, Michigan–(Newsfile Corp. – February 22, 2021) – Lotus Ventures Inc. (CSE: J) announced today the Company will be presenting at the Benzinga Cannabis Capital Conference taking place on February 25-26, 2021. We invite Lotus shareholders and all interested parties to join us for a full day of networking, deal making and discovery. Sign up to get a free spectator pass for the event: https://events.benzinga.com/ccc-free-registration.
On behalf of Lotus Investor Relations, Daniel McRobert will be presenting at 9:30 a.m. Pacific Standard Time on Friday, February 26th, 2021. Daniel has managed the Investor Relations and Marketing Communications for Lotus over the past three years and brings a dynamic angle merging the corporate and cannabis culture in one.
A copy of the presentation will be available on the Company’s website after the event at lotuscannabis.ca/investors. If you would like to receive a copy directly or if you have any questions regarding the event, please connect with Daniel.
About Benzinga Cannabis Capital Conference
Benzinga’s virtual Cannabis Capital Conference is guaranteed to offer participants all the benefits of an immersive and robust in-person conference from any remote location. The conference will feature an interactive forum of live presentations from top CEOs, investors, and leaders in the cannabis space. Don’t miss this opportunity to connect with THE cannabis movers and shakers from across the globe.
About Lotus Ventures Inc.
Lotus Ventures Inc. is the publicly traded licensed producer and owner of Lotus Cannabis, a premium cannabis brand in Canada. Situated on 23 acres in BC’s North Okanagan region, Lotus created a scalable, purpose-built facility designed for the low-cost of production of rare cannabis genetics.
Utilizing an improved facility design, the next phase of growth will involve scaling our profitable prototype operation to enable fuller utilization of our large genetic library of over 200 cannabis strains. The Lotus team combines decades of real estate development and cultivation experience and created the ideal facility for growing medical-grade cannabis. Lotus operates a high-performance harvest schedule providing consumers with a quality product and a consistent experience.
Lotus is listed on the Canadian Securities Exchange (CSE) under the symbol "J", on the OTC Markets (OTC) under the symbol "LTTSF" and in Frankfurt (FRA) under the symbol "LV9".
For more information and/or to register for the conference please visit: https://events.benzinga.com/ccc-free-registration.
We look forward to seeing you there.
For further information:
Lotus Ventures Inc.
Daniel McRobert, Investor Relations
604-842-4625
[email protected]
https://lotuscannabis.ca/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/75001
Cannabis
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis7 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis6 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan5 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis2 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa